Cargando…

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients

BACKGROUND: The 70-gene signature (70-GS, MammaPrint) test has been recommended by the main guidelines to evaluate prognosis and chemotherapy benefit of hormonal receptor positive human epidermal receptor 2 negative (HR + /Her2−) early breast cancer (BC). However, this expensive assay is not always...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Bo, Xu, Ying, Yao, Ru, Cao, Xi, Zhou, Xingtong, Hao, Zhixin, Zhang, Yanna, Wang, Changjun, Shen, Songjie, Luo, Yanwen, Zhu, Qingli, Ren, Xinyu, Kong, Lingyan, Zhou, Yidong, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637017/
https://www.ncbi.nlm.nih.gov/pubmed/37946210
http://dx.doi.org/10.1186/s12967-023-04523-7
_version_ 1785133319011172352
author Pan, Bo
Xu, Ying
Yao, Ru
Cao, Xi
Zhou, Xingtong
Hao, Zhixin
Zhang, Yanna
Wang, Changjun
Shen, Songjie
Luo, Yanwen
Zhu, Qingli
Ren, Xinyu
Kong, Lingyan
Zhou, Yidong
Sun, Qiang
author_facet Pan, Bo
Xu, Ying
Yao, Ru
Cao, Xi
Zhou, Xingtong
Hao, Zhixin
Zhang, Yanna
Wang, Changjun
Shen, Songjie
Luo, Yanwen
Zhu, Qingli
Ren, Xinyu
Kong, Lingyan
Zhou, Yidong
Sun, Qiang
author_sort Pan, Bo
collection PubMed
description BACKGROUND: The 70-gene signature (70-GS, MammaPrint) test has been recommended by the main guidelines to evaluate prognosis and chemotherapy benefit of hormonal receptor positive human epidermal receptor 2 negative (HR + /Her2−) early breast cancer (BC). However, this expensive assay is not always accessible and affordable worldwide. Based on our previous study, we established nomogram models to predict the binary and quartile categorized risk of 70-GS. METHODS: We retrospectively analyzed a consecutive cohort of 150 female patients with HR + /Her2− BC and eligible 70-GS test. Comparison of 40 parameters including the patients’ medical history risk factors, imaging features and clinicopathological characteristics was performed between patients with high risk (N = 62) and low risk (N = 88) of 70-GS test, whereas risk calculations from established models including Clinical Treatment Score Post-5 years (CTS5), Immunohistochemistry 3 (IHC3) and Nottingham Prognostic Index (NPI) were also compared between high vs low binary risk of 70-GS and among ultra-high (N = 12), high (N = 50), low (N = 65) and ultra-low (N = 23) quartile categorized risk of 70-GS. The data of 150 patients were randomly split by 4:1 ratio with training set of 120 patients and testing set 30 patients. Univariate analyses and multivariate logistic regression were performed to establish the two nomogram models to predict the the binary and quartile categorized risk of 70-GS. RESULTS: Compared to 70-GS low-risk patients, the high-risk patients had significantly less cardiovascular co-morbidity (p = 0.034), more grade 3 BC (p = 0.006), lower progesterone receptor (PR) positive percentage (p = 0.007), more Ki67 high BC (≥ 20%, p < 0.001) and no significant differences in all the imaging parameters of ultrasound and mammogram. The IHC3 risk and the NPI calculated score significantly correlated with both the binary and quartile categorized 70-GS risk classifications (both p < 0.001). The area under curve (AUC) of receiver-operating curve (ROC) of nomogram for binary risk prediction were 0.826 (C-index 0.903, 0.799–1.000) for training and 0.737 (C-index 0.785, 0.700–0.870) for validation dataset respectively. The AUC of ROC of nomogram for quartile risk prediction was 0.870 (C-index 0.854, 0.746–0.962) for training and 0.592 (C-index 0.769, 0.703–0.835) for testing set. The prediction accuracy of the nomogram for quartile categorized risk groups were 55.0% (likelihood ratio tests, p < 0.001) and 53.3% (p = 0.04) for training and validation, which more than double the baseline probability of 25%. CONCLUSIONS: To our knowledge, we are the first to establish easy-to-use nomograms to predict the individualized binary (high vs low) and the quartile categorized (ultra-high, high, low and ultra-low) risk classification of 70-GS test with fair performance, which might provide information for treatment choice for those who have no access to the 70-GS testing. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04523-7.
format Online
Article
Text
id pubmed-10637017
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106370172023-11-11 Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients Pan, Bo Xu, Ying Yao, Ru Cao, Xi Zhou, Xingtong Hao, Zhixin Zhang, Yanna Wang, Changjun Shen, Songjie Luo, Yanwen Zhu, Qingli Ren, Xinyu Kong, Lingyan Zhou, Yidong Sun, Qiang J Transl Med Research BACKGROUND: The 70-gene signature (70-GS, MammaPrint) test has been recommended by the main guidelines to evaluate prognosis and chemotherapy benefit of hormonal receptor positive human epidermal receptor 2 negative (HR + /Her2−) early breast cancer (BC). However, this expensive assay is not always accessible and affordable worldwide. Based on our previous study, we established nomogram models to predict the binary and quartile categorized risk of 70-GS. METHODS: We retrospectively analyzed a consecutive cohort of 150 female patients with HR + /Her2− BC and eligible 70-GS test. Comparison of 40 parameters including the patients’ medical history risk factors, imaging features and clinicopathological characteristics was performed between patients with high risk (N = 62) and low risk (N = 88) of 70-GS test, whereas risk calculations from established models including Clinical Treatment Score Post-5 years (CTS5), Immunohistochemistry 3 (IHC3) and Nottingham Prognostic Index (NPI) were also compared between high vs low binary risk of 70-GS and among ultra-high (N = 12), high (N = 50), low (N = 65) and ultra-low (N = 23) quartile categorized risk of 70-GS. The data of 150 patients were randomly split by 4:1 ratio with training set of 120 patients and testing set 30 patients. Univariate analyses and multivariate logistic regression were performed to establish the two nomogram models to predict the the binary and quartile categorized risk of 70-GS. RESULTS: Compared to 70-GS low-risk patients, the high-risk patients had significantly less cardiovascular co-morbidity (p = 0.034), more grade 3 BC (p = 0.006), lower progesterone receptor (PR) positive percentage (p = 0.007), more Ki67 high BC (≥ 20%, p < 0.001) and no significant differences in all the imaging parameters of ultrasound and mammogram. The IHC3 risk and the NPI calculated score significantly correlated with both the binary and quartile categorized 70-GS risk classifications (both p < 0.001). The area under curve (AUC) of receiver-operating curve (ROC) of nomogram for binary risk prediction were 0.826 (C-index 0.903, 0.799–1.000) for training and 0.737 (C-index 0.785, 0.700–0.870) for validation dataset respectively. The AUC of ROC of nomogram for quartile risk prediction was 0.870 (C-index 0.854, 0.746–0.962) for training and 0.592 (C-index 0.769, 0.703–0.835) for testing set. The prediction accuracy of the nomogram for quartile categorized risk groups were 55.0% (likelihood ratio tests, p < 0.001) and 53.3% (p = 0.04) for training and validation, which more than double the baseline probability of 25%. CONCLUSIONS: To our knowledge, we are the first to establish easy-to-use nomograms to predict the individualized binary (high vs low) and the quartile categorized (ultra-high, high, low and ultra-low) risk classification of 70-GS test with fair performance, which might provide information for treatment choice for those who have no access to the 70-GS testing. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04523-7. BioMed Central 2023-11-09 /pmc/articles/PMC10637017/ /pubmed/37946210 http://dx.doi.org/10.1186/s12967-023-04523-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pan, Bo
Xu, Ying
Yao, Ru
Cao, Xi
Zhou, Xingtong
Hao, Zhixin
Zhang, Yanna
Wang, Changjun
Shen, Songjie
Luo, Yanwen
Zhu, Qingli
Ren, Xinyu
Kong, Lingyan
Zhou, Yidong
Sun, Qiang
Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
title Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
title_full Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
title_fullStr Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
title_full_unstemmed Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
title_short Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
title_sort nomogram prediction of the 70-gene signature (mammaprint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among chinese breast cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637017/
https://www.ncbi.nlm.nih.gov/pubmed/37946210
http://dx.doi.org/10.1186/s12967-023-04523-7
work_keys_str_mv AT panbo nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT xuying nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT yaoru nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT caoxi nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT zhouxingtong nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT haozhixin nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT zhangyanna nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT wangchangjun nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT shensongjie nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT luoyanwen nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT zhuqingli nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT renxinyu nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT konglingyan nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT zhouyidong nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients
AT sunqiang nomogrampredictionofthe70genesignaturemammaprintbinaryandquartilecategorizedriskusingmedicalhistoryimagingfeaturesandclinicopathologicaldataamongchinesebreastcancerpatients